Compare FTEK & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTEK | ELUT |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Pollution Control Equipment | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 41.9M |
| IPO Year | 1997 | 2020 |
| Metric | FTEK | ELUT |
|---|---|---|
| Price | $2.15 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 627.7K | 92.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,467,000.00 | $12,293,000.00 |
| Revenue This Year | $14.17 | N/A |
| Revenue Next Year | $11.62 | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $0.50 |
| 52 Week High | $3.64 | $2.60 |
| Indicator | FTEK | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 76.81 | 45.11 |
| Support Level | $1.49 | $0.86 |
| Resistance Level | $3.51 | $0.99 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 79.72 | 24.24 |
Fuel Tech Inc is a technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling for boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.